SCHEDULE: Stonepine Capital Discloses 10.6% Stake in Quoin Pharma

Stonepine Capital Management and its affiliates have reported a 10.6% beneficial ownership stake in Quoin Pharmaceuticals, Ltd., primarily through American Depositary Shares and warrants.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico collectively beneficially own 3,271,100 Ordinary Shares of Quoin Pharmaceuticals, Ltd.
• This represents 10.6% of the outstanding Ordinary Shares.
• The holdings include 93,460 American Depositary Shares (ADSs), pre-funded warrants to acquire 81,212 ADSs, and ordinary warrants to acquire 484,848 ADSs.
• Each ADS represents 35 Ordinary Shares.
• The percentage is calculated based on 29,364,180 Ordinary Shares outstanding as of November 3, 2025, plus 1,400,000 Ordinary Shares issued from pre-funded warrant exercise.
• The pre-funded and ordinary warrants are currently not exercisable due to a 9.9% beneficial ownership limitation.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest and state the securities were not acquired for the purpose of changing or influencing control.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development due to increased institutional ownership, but the unexercisable warrants introduce a degree of uncertainty regarding the full extent of Stonepine's immediate influence or commitment.

Positives

• Increased institutional ownership by Stonepine Capital, potentially signaling confidence in Quoin Pharmaceuticals.

Negatives

• A significant portion of the reported beneficial ownership is tied to warrants that are currently unexercisable due to a 9.9% beneficial ownership limitation, restricting immediate full conversion.

Risks

• The inability to exercise a substantial portion of warrants (pre-funded and ordinary warrants) due to a 9.9% beneficial ownership limitation means Stonepine Capital cannot fully realize its potential ownership or influence until this limitation is addressed or waived.

Industry Context

StockSavvy.ai notes that an increase in institutional ownership, such as this disclosure by Stonepine Capital, can sometimes be interpreted by the market as a vote of confidence in a company's long-term prospects, particularly in the biotechnology sector where development timelines are long and capital intensive. However, the specific limitations on warrant exercisability introduce a nuance, suggesting a strategic, yet currently constrained, position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could be seen positively, potentially increasing investor confidence. However, the limitations on warrant exercise might temper expectations regarding immediate strategic impact from this shareholder.

Key Dates

Recommendation

The disclosure of a significant 10.6% stake by Stonepine Capital in Quoin Pharmaceuticals suggests institutional interest, which is generally a positive signal. However, the fact that a substantial portion of this ownership is tied to warrants that are currently unexercisable due to a beneficial ownership limitation introduces a degree of uncertainty. This prevents Stonepine from fully realizing its potential stake or exerting full influence immediately. Therefore, a 'hold' recommendation is appropriate as the market assesses the implications of this constrained institutional position and any future actions regarding the warrants.

Keywords

Quoin Pharmaceuticals, Stonepine Capital, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Warrants, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals